Matterway GmbH legal imprint — company registration, contact information, and legal disclosures.

Seeq, a global leader in Industrial AI, has announced a collaboration with Cognizant to accelerate manufacturing analytics adoption in life sciences and pharmaceuticals. The partnership combines Seeq's industrial AI and analytics platform with Cognizant's advisory, implementation, and change management capabilities. The collaboration will initially focus on helping pharmaceutical manufacturers improve operational efficiency through Seeq's Operational Efficiency and OEE Industry Solution. This enables companies to move from site-specific dashboards to standardised performance management across multiple sites. For regulated pharmaceutical environments, Seeq offers purpose-built capabilities designed to support compliance with 21 CFR Part 11 requirements, including auditability and data integrity features. The partnership aims to help manufacturers operationalise use cases such as Continued Process Verification and Overall Equipment Effectiveness. Whilst launching in life sciences, both companies see potential to expand the collaboration into other complex manufacturing sectors.

Cognizant and EPAM Systems shares jumped approximately 7% on Thursday following strong results from industry bellwether Accenture. Accenture's fiscal fourth-quarter revenue of $18.68 billion exceeded the top of its own guidance range and analyst expectations of $18.04 billion. Earnings per share of $3.29 also beat the $3.18 consensus. Accenture booked $22.2 billion in new work during the quarter, bringing its annual total to a record $84.5 billion. The results suggest large companies are resuming spending on IT services and push back against concerns that AI would reduce demand for consulting work. Cognizant and EPAM, which offer similar services including cloud migration and systems modernisation, are benefiting from investor optimism that Accenture's strong performance reflects broader industry trends. Both companies will report their own quarterly results in October and November, which will confirm whether the increased demand extends beyond Accenture.